What is HC Wainwright's Estimate for ARCT FY2028 Earnings?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Investment analysts at HC Wainwright raised their FY2028 earnings per share estimates for shares of Arcturus Therapeutics in a research report issued to clients and investors on Friday, November 8th. HC Wainwright analyst E. Arce now forecasts that the biotechnology company will post earnings per share of $13.21 for the year, up from their prior forecast of $12.84. HC Wainwright has a "Buy" rating and a $63.00 price target on the stock. The consensus estimate for Arcturus Therapeutics' current full-year earnings is ($2.60) per share.

A number of other analysts have also recently weighed in on ARCT. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Leerink Partners initiated coverage on Arcturus Therapeutics in a report on Monday, August 12th. They set an "outperform" rating and a $70.00 price target on the stock. Finally, Leerink Partnrs upgraded Arcturus Therapeutics to a "strong-buy" rating in a research report on Monday, August 12th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $71.40.

Arcturus Therapeutics Price Performance

Shares of ARCT stock traded up $0.75 during trading hours on Monday, hitting $20.37. The stock had a trading volume of 671,217 shares, compared to its average volume of 316,494. The stock's 50 day moving average is $20.61 and its 200 day moving average is $24.21. Arcturus Therapeutics has a twelve month low of $17.26 and a twelve month high of $45.00.

Institutional Investors Weigh In On Arcturus Therapeutics

Several institutional investors have recently made changes to their positions in ARCT. Russell Investments Group Ltd. acquired a new stake in shares of Arcturus Therapeutics in the first quarter valued at about $40,000. nVerses Capital LLC acquired a new stake in shares of Arcturus Therapeutics during the 3rd quarter valued at approximately $42,000. Quest Partners LLC boosted its stake in shares of Arcturus Therapeutics by 3,283.5% during the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company's stock worth $90,000 after acquiring an additional 3,579 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in shares of Arcturus Therapeutics by 10.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company's stock worth $152,000 after acquiring an additional 428 shares during the period. Finally, Public Employees Retirement System of Ohio increased its stake in Arcturus Therapeutics by 63.8% in the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company's stock valued at $156,000 after purchasing an additional 1,800 shares in the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the sale, the chief operating officer now owns 435,334 shares of the company's stock, valued at approximately $9,037,533.84. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 15.30% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.